Abstract: [Problem] The present invention addresses the problem of providing a muscle function-improving agent for suppressing or improving the decline of muscular functions due to aging. [Solution] Provided is a muscle function-improving agent for suppressing or improving the functional decline of skeletal muscle due to aging, the muscle function-improving agent containing, as an active ingredient, at least one peptide selected from among the following (1)-(3), or a salt thereof: (1) a peptide consisting of the amino acid sequence represented by SEC) ID NO: 1; (2) a peptide which is the fragment of human osteopontin, and in which the C-terminal amino acid sequence is the amino acid sequence represented by SEQ ID NO: 1; and (3) a peptide which consists of an amino acid sequence obtained by substituting, adding, or deleting one or more amino acids in the amino acid sequence of the peptide in (1) or (2), and has the action of suppressing or ameliorating the functional decline of skeletal muscle due to aging.

Abstract: The present invention provides an agent for promoting skeletal muscle injury repair which agent comprises at least one peptide selected from the following (1) to (4): (1) a peptide consisting of the amino acid sequence of SEQ ID NO: 1, (2) a peptide consisting of the amino acid sequence of SEQ ID NO: 2, (3) a peptide consisting of the amino acid sequence of SEQ ID NO: 3, and (4) a peptide which is a human osteopontin fragment and has the amino acid sequence of SEQ ID NO: 1, 2, or 3 at the C-terminus, or a salt thereof as an active ingredient.

Abstract: The present invention provides an agent for promoting skeletal muscle injury repair which agent comprises at least one peptide selected from the following (1) to (4): (1) a peptide consisting of the amino acid sequence of SEQ ID NO: 1, (2) a peptide consisting of the amino acid sequence of SEQ ID NO: 2, (3) a peptide consisting of the amino acid sequence of SEQ ID NO: 3, and (4) a peptide which is a human osteopontin fragment and has the amino acid sequence of SEQ ID NO: 1, 2, or 3 at the C-terminus, or a salt thereof as an active ingredient.

Abstract: It is found that a SVVYGLR peptide (SEQ ID NO: 1) can promote proliferation of mesenchymal cells such as marrow-derived mesenchymal stem cells and dental pulp cells. A carbonate apatite-collagen sponge containing the SVVYGLR peptide (SEQ ID NO: 1) is useful as a biomaterial for the regeneration of bone marrow or dental pulp. It becomes possible to provide a skeletal system biomaterial which is capable of promoting the proliferation of the mesenchymal cells and is useful as artificial bone marrow or artificial dental pulp for repairing a defect in a bone marrow tissue or a dental pulp tissue.

Abstract: It is found that a SVVYGLR peptide (SEQ ID NO: 1) can promote proliferation of mesenchymal cells such as marrow-derived mesenchymal stem cells and dental pulp cells. A carbonate apatite-collagen sponge containing the SVVYGLR peptide (SEQ ID NO: 1) is useful as a biomaterial for the regeneration of bone marrow or dental pulp. It becomes possible to provide a skeletal system biomaterial which is capable of promoting the proliferation of the mesenchymal cells and is useful as artificial bone marrow or artificial dental pulp for repairing a defect in a bone marrow tissue or a dental pulp tissue.

Abstract: A novel angiogenesis drug which can be clinically used for therapies of human or the like is disclosed. The angiogenesis drug according to the present invention comprises a peptide as an effective component, which has a prescribed amino acid sequence and has an angiogenesis action.

Abstract: A novel angiogenesis drug which can be clinically used for therapies of human or the like is disclosed. The angiogenesis drug according to the present invention comprises a peptide as an effective component, which has a prescribed amino acid sequence and has an angiogenesis action.